This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Diabetes, Metabolic Syndrome And Cardiovascular Disease

Table 3.13: Death Rate from Cardiovascular Diseases by Country, 2008 43

Table 3.14: Percentage of Adults Smokers by Country, 2008 47

Table 3.15: Selected Potential Patent Expirations of Cardiac Care Drugs, 2012-2013 48

Table 3.16: Worldwide Market for Cardiac Care Therapeutics, 2007-2014 49

Table 4.1: Global R&D Spending in the Pharmaceutical Industry, 2008-2012 56

Table 4.2: Pharmaceutical Companies Ranked by Total R&D Expenditures, 2011 56

Table 4.3: Leading Therapy Classes for R&D, 2012 57

Table 4.4: Global Pharmaceutical Sales by Region and Country, 2010 and 2015, and CAGR 2006-2010 and 2011-2015 58

Table 4.5: World Pharmaceutical Sales Share by Region, 2010 59

Table 4.6: Top Ten Global Pharmaceutical Companies by Global Sales, 2011 59

Table 4.7: Leading Ten Therapeutic Classes by U.S. Sales, 2006-2011 60

Table 4.8: Top Ten Therapeutic Classes by U.S. Dispensed Prescriptions, 2006-2011 60

Table 4.9: Leading Therapy Classes by Global Pharmaceutical Sales, 2015, and CAGR 2011-2015 61

Table 4.10: Top Selling Drugs in the U.S., 2010 61

Table 4.11: Worldwide Anti-Diabetes Drug Market, 2008-2016 63

Table 4.12: Oral Anti-Diabetic Therapy Major World Markets, 2010 63

Table 4.13: The Leading Five Anti-Diabetics by Sales, 2011 65

Table 4.14: American College of Physicians 2012 Practical Guideline for the Use of Anti-Diabetes Drugs for Type 2 Diabetes 66

Table 4.15: Summary of Glucose-Lowering Interventions as Monotherapy 70

Table 5.1: Classes of Non-Insulin Hypoglycemic Agents 73

Table 5.2: Non-Insulin Hypoglycemic Drugs Used to Treat Type 2 Diabetes, 2012 75

Table 5.3: Relative Efficacy of Diabetes Drugs 75

Table 5.4: Average Dose and Cost Comparison of Oral Hypoglycemic Agents 76

Table 5.5: Fixed-Dose Oral Anti-Diabetes Drug Combinations 88

Table 5.6: Delivery Method of Non-Insulin Anti-Diabetes Drugs in the Pipeline, 2011 93

Table 5.7: GLP-1 Agonist Pipeline: Selected Drugs in Development that Target GLP-1 94

Table 5.8: DPP-IV Inhibitor Pipeline 95

Table 5.9: Summary of Emerging Non-Insulin Anti-Diabetes Drug Categories 97

7 of 9

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs